US › Healthcare

Akari Therapeutics PLC (AKTX)

US · Healthcare · Biotechnology

$8.18-7.47%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.8M

EPS

$-2.69

EPS estimate

$-1.04

EPS came in at -2.69 against a street estimate of -1.04 — a miss of 158.5%.

Key statistics

Market cap

$18.1M

Forward P/E

0.0

P/B

1.01

Book value

$10.62

EPS (TTM)

$0.00

52-week high

$33.60

52-week low

$3.02

50-day MA

$9.05

200-day MA

$9.24

Beta

1.44

Analyst view

Analysts rate Akari Therapeutics PLC a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $25.50.

Shareholding

Insiders

13.25%

Institutions

10.52%

Largest institutional holders

Fund	Stake
Mmcap International Inc. Spc	4.38%
Cresset Asset Management, LLC	0.90%
Jane Street Group LLC	0.68%
HRT FINANCIAL LLC	0.60%
IFP Advisors, LLC	0.01%
SBI Securities Co Ltd	0.00%
Caitong International Asset Management Co., Limited.	0.00%
Northwestern Mutual Wealth Management Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Akari Therapeutics PLC — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.